Phase II study of sulofenur (LY 186641) - A novel antineoplastic agent in advanced non-small cell lung cancer

Nikhil C. Munshi, David E. Seitz, Frank Fossella, Scott M. Lippman, Lawrence Einhorn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Sulofenur is a member of a new class of antineoplastic agents with a novel chemical structure and unique pharmacological and biological properties. Preclinical studies have demonstrated a wide spectrum of antitumor activity against murine solid tumors and human tumor xenografts. In phase I trials, only mild toxicities were observed. Twenty-six patients (pts), two of whom were inevaluable, with advanced non small cell lung cancer without prior chemotherapy were entered on this phase II trial. Pts received 800 mg/m2 sulofenur po Monday-Friday × 21 days, q 28 days. Seventeen male and 9 female pts with median performance status 1 received a median of 2 courses. Twenty pts had stage IV disease and 19 pts had adenocarcinoma, 6 squamous cell and 1 undifferentiated carcinoma. The main toxicity was grade 1 to 3 anemia in 16 (62%) pts, with hemolysis noted in 9 pts. Although methemoglobinemia was observed in 19 pts, it was severe in only 3 pts. Transient elevation of alkaline phosphatase was seen in 11 pts and one pt had a minor abnormality in glucose metabolism. Other common chemotherapy related side effects such as granulocytopenia or alopecia were not encountered with this agent. Of 24 evaluable pts, two pts had stable disease or minor response and 22 pts had progressive disease. In conclusion although sulofenur had only minor side effects, in the dosage and schedule used, it did not produce any significant response in advanced non-small cell lung cancer.

Original languageEnglish
Pages (from-to)87-90
Number of pages4
JournalInvestigational New Drugs
Volume11
Issue number1
DOIs
StatePublished - Feb 1993

Fingerprint

sulofenur
Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Methemoglobinemia
Drug Therapy
Agranulocytosis

Keywords

  • lung cancer
  • methemoglobinemia
  • sulofenur

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II study of sulofenur (LY 186641) - A novel antineoplastic agent in advanced non-small cell lung cancer. / Munshi, Nikhil C.; Seitz, David E.; Fossella, Frank; Lippman, Scott M.; Einhorn, Lawrence.

In: Investigational New Drugs, Vol. 11, No. 1, 02.1993, p. 87-90.

Research output: Contribution to journalArticle

Munshi, Nikhil C. ; Seitz, David E. ; Fossella, Frank ; Lippman, Scott M. ; Einhorn, Lawrence. / Phase II study of sulofenur (LY 186641) - A novel antineoplastic agent in advanced non-small cell lung cancer. In: Investigational New Drugs. 1993 ; Vol. 11, No. 1. pp. 87-90.
@article{e9d3b1c1004f49b8a1b5ecbe7ccf1101,
title = "Phase II study of sulofenur (LY 186641) - A novel antineoplastic agent in advanced non-small cell lung cancer",
abstract = "Sulofenur is a member of a new class of antineoplastic agents with a novel chemical structure and unique pharmacological and biological properties. Preclinical studies have demonstrated a wide spectrum of antitumor activity against murine solid tumors and human tumor xenografts. In phase I trials, only mild toxicities were observed. Twenty-six patients (pts), two of whom were inevaluable, with advanced non small cell lung cancer without prior chemotherapy were entered on this phase II trial. Pts received 800 mg/m2 sulofenur po Monday-Friday × 21 days, q 28 days. Seventeen male and 9 female pts with median performance status 1 received a median of 2 courses. Twenty pts had stage IV disease and 19 pts had adenocarcinoma, 6 squamous cell and 1 undifferentiated carcinoma. The main toxicity was grade 1 to 3 anemia in 16 (62{\%}) pts, with hemolysis noted in 9 pts. Although methemoglobinemia was observed in 19 pts, it was severe in only 3 pts. Transient elevation of alkaline phosphatase was seen in 11 pts and one pt had a minor abnormality in glucose metabolism. Other common chemotherapy related side effects such as granulocytopenia or alopecia were not encountered with this agent. Of 24 evaluable pts, two pts had stable disease or minor response and 22 pts had progressive disease. In conclusion although sulofenur had only minor side effects, in the dosage and schedule used, it did not produce any significant response in advanced non-small cell lung cancer.",
keywords = "lung cancer, methemoglobinemia, sulofenur",
author = "Munshi, {Nikhil C.} and Seitz, {David E.} and Frank Fossella and Lippman, {Scott M.} and Lawrence Einhorn",
year = "1993",
month = "2",
doi = "10.1007/BF00873919",
language = "English",
volume = "11",
pages = "87--90",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II study of sulofenur (LY 186641) - A novel antineoplastic agent in advanced non-small cell lung cancer

AU - Munshi, Nikhil C.

AU - Seitz, David E.

AU - Fossella, Frank

AU - Lippman, Scott M.

AU - Einhorn, Lawrence

PY - 1993/2

Y1 - 1993/2

N2 - Sulofenur is a member of a new class of antineoplastic agents with a novel chemical structure and unique pharmacological and biological properties. Preclinical studies have demonstrated a wide spectrum of antitumor activity against murine solid tumors and human tumor xenografts. In phase I trials, only mild toxicities were observed. Twenty-six patients (pts), two of whom were inevaluable, with advanced non small cell lung cancer without prior chemotherapy were entered on this phase II trial. Pts received 800 mg/m2 sulofenur po Monday-Friday × 21 days, q 28 days. Seventeen male and 9 female pts with median performance status 1 received a median of 2 courses. Twenty pts had stage IV disease and 19 pts had adenocarcinoma, 6 squamous cell and 1 undifferentiated carcinoma. The main toxicity was grade 1 to 3 anemia in 16 (62%) pts, with hemolysis noted in 9 pts. Although methemoglobinemia was observed in 19 pts, it was severe in only 3 pts. Transient elevation of alkaline phosphatase was seen in 11 pts and one pt had a minor abnormality in glucose metabolism. Other common chemotherapy related side effects such as granulocytopenia or alopecia were not encountered with this agent. Of 24 evaluable pts, two pts had stable disease or minor response and 22 pts had progressive disease. In conclusion although sulofenur had only minor side effects, in the dosage and schedule used, it did not produce any significant response in advanced non-small cell lung cancer.

AB - Sulofenur is a member of a new class of antineoplastic agents with a novel chemical structure and unique pharmacological and biological properties. Preclinical studies have demonstrated a wide spectrum of antitumor activity against murine solid tumors and human tumor xenografts. In phase I trials, only mild toxicities were observed. Twenty-six patients (pts), two of whom were inevaluable, with advanced non small cell lung cancer without prior chemotherapy were entered on this phase II trial. Pts received 800 mg/m2 sulofenur po Monday-Friday × 21 days, q 28 days. Seventeen male and 9 female pts with median performance status 1 received a median of 2 courses. Twenty pts had stage IV disease and 19 pts had adenocarcinoma, 6 squamous cell and 1 undifferentiated carcinoma. The main toxicity was grade 1 to 3 anemia in 16 (62%) pts, with hemolysis noted in 9 pts. Although methemoglobinemia was observed in 19 pts, it was severe in only 3 pts. Transient elevation of alkaline phosphatase was seen in 11 pts and one pt had a minor abnormality in glucose metabolism. Other common chemotherapy related side effects such as granulocytopenia or alopecia were not encountered with this agent. Of 24 evaluable pts, two pts had stable disease or minor response and 22 pts had progressive disease. In conclusion although sulofenur had only minor side effects, in the dosage and schedule used, it did not produce any significant response in advanced non-small cell lung cancer.

KW - lung cancer

KW - methemoglobinemia

KW - sulofenur

UR - http://www.scopus.com/inward/record.url?scp=0027215746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027215746&partnerID=8YFLogxK

U2 - 10.1007/BF00873919

DO - 10.1007/BF00873919

M3 - Article

C2 - 8394298

AN - SCOPUS:0027215746

VL - 11

SP - 87

EP - 90

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -